Matches the official registry, and the clinic's own site confirms self-pay GLP-1 care plus visitor acceptance or Korean guidance. "Info verified" means we confirmed the facts above. It is not an endorsement of medical quality or outcomes.
What we verified
Each item shows the source and the date we checked the clinic's official site. Items without evidence are marked 'Unverified'.
- GLP-1 (Mounjaro) self-pay treatment
- YesSource: abclinic.jp (new window) · Checked 2026-11-14
- Accepts visitors
- Unverified
- Korean support
- Korean-speaking staffSource: abclinic.jp (new window) · Checked 2026-11-14
- Same-day visit
- Unverified
- Hotel delivery
- Unverified
- In-clinic pickup
- Unverified
- English prescription / letter
- Unverified
Prices published by the clinic
Copied from the clinic's site. Consultation and delivery fees may be extra; prices change.
| Item | JPY | Tax | Checked |
|---|---|---|---|
| マンジャロ 2.5mg 2本 | ¥12,000 | incl. | 2026-11-14 · Source (new window) |
| マンジャロ 2.5mg 4本 | ¥19,200 | incl. | 2026-11-14 · Source (new window) |
| マンジャロ 5mg 2本 | ¥24,000 | incl. | 2026-11-14 · Source (new window) |
| マンジャロ 5mg 4本 | ¥36,000 | incl. | 2026-11-14 · Source (new window) |
| 血液検査(初回のみ) | ¥5,500 | incl. | 2026-11-14 · Source (new window) |
Risks to know
GLP-1 injections commonly cause nausea, vomiting, diarrhea and constipation; rare reports include acute pancreatitis, hypoglycemia and vision problems (NAION). In Japan, Mounjaro is approved for type 2 diabetes only; weight-management use is off-label. Medicines prescribed abroad do not appear in Korea's DUR records and are hard to cover under its adverse-reaction relief scheme.
SushiMedi does not advertise clinics or medicines and does not refer patients. Treatment decisions are made by the local doctor. Medicines prescribed abroad are not covered by Korea's adverse-reaction relief scheme. Follow MFDS and Korea Customs rules when bringing medicines home.